No Data
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
J&J Talc Claimants Lose Bid to Block Bankruptcy Bid
J&J Reports Positive Phase 3 Data for Nipocalimab for Neuromuscular Disease
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial
Johnson & Johnson (JNJ) said Friday results from a phase 3 study of nipocalimab in generalized myasthenia gravis were "positive." Patients treated with nipocalimab plus standard of care achieved super
Express News | J&J - Papillon Study Met Its Primary Endpoint
Express News | Rybrevant®▼ (Amivantamab) in Combination With Chemotherapy Is First Therapy Approved by European Commission for First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer With Activating Egfr Exon 20 Insertion Mutations